---
document_datetime: 2025-12-29 12:48:24
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/budesonide-formoterol-teva.html
document_name: budesonide-formoterol-teva.html
version: success
processing_time: 0.1272073
conversion_datetime: 2025-12-30 13:07:59.777865
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Budesonide/Formoterol Teva

[RSS](/en/individual-human-medicine.xml/66056)

##### Withdrawn

This medicine's authorisation has been withdrawn

budesonide / formoterol Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Budesonide/Formoterol Teva](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 16 December 2016, the European Commission withdrew the marketing authorisation for Budesonide/Formoterol Teva (budesonide / formoterol) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva Pharma B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Budesonide/Formoterol Teva was granted marketing authorisation in the EU on 19 November 2014 for treatment of asthma and chronic obstructive pulmonary disease (COPD). The marketing authorisation was initially valid for a 5-year period. Budesonide/Formoterol Teva was a duplicate of DuoResp Spiromax, which is marketed in several EU countries.

The European Public Assessment Report (EPAR) for Budesonide/Formoterol Teva is updated accordingly to indicate that the marketing authorisation is no longer valid.

Budesonide/Formoterol Teva : EPAR - Summary for the public

Reference Number: EMA/601019/2014

English (EN) (218.08 KB - PDF)

**First published:** 04/12/2014

**Last updated:** 31/01/2017

[View](/en/documents/overview/budesonideformoterol-teva-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-303)

български (BG) (283.13 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/bg/documents/overview/budesonideformoterol-teva-epar-summary-public_bg.pdf)

español (ES) (218.08 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/es/documents/overview/budesonideformoterol-teva-epar-summary-public_es.pdf)

čeština (CS) (286.09 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/cs/documents/overview/budesonideformoterol-teva-epar-summary-public_cs.pdf)

dansk (DA) (218.16 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/da/documents/overview/budesonideformoterol-teva-epar-summary-public_da.pdf)

Deutsch (DE) (221.56 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/de/documents/overview/budesonideformoterol-teva-epar-summary-public_de.pdf)

eesti keel (ET) (227.26 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/et/documents/overview/budesonideformoterol-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (288.69 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/el/documents/overview/budesonideformoterol-teva-epar-summary-public_el.pdf)

français (FR) (241.63 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/fr/documents/overview/budesonideformoterol-teva-epar-summary-public_fr.pdf)

hrvatski (HR) (239.52 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/hr/documents/overview/budesonideformoterol-teva-epar-summary-public_hr.pdf)

italiano (IT) (216.72 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/it/documents/overview/budesonideformoterol-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (261.49 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/lv/documents/overview/budesonideformoterol-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (267.39 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/lt/documents/overview/budesonideformoterol-teva-epar-summary-public_lt.pdf)

magyar (HU) (260.81 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/hu/documents/overview/budesonideformoterol-teva-epar-summary-public_hu.pdf)

Malti (MT) (266.82 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/mt/documents/overview/budesonideformoterol-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (218.13 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/nl/documents/overview/budesonideformoterol-teva-epar-summary-public_nl.pdf)

polski (PL) (263.5 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/pl/documents/overview/budesonideformoterol-teva-epar-summary-public_pl.pdf)

português (PT) (240.68 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/pt/documents/overview/budesonideformoterol-teva-epar-summary-public_pt.pdf)

română (RO) (245.53 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/ro/documents/overview/budesonideformoterol-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (286.28 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/sk/documents/overview/budesonideformoterol-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (275.44 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/sl/documents/overview/budesonideformoterol-teva-epar-summary-public_sl.pdf)

Suomi (FI) (215.95 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/fi/documents/overview/budesonideformoterol-teva-epar-summary-public_fi.pdf)

svenska (SV) (217.83 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/sv/documents/overview/budesonideformoterol-teva-epar-summary-public_sv.pdf)

Budesonide/Formoterol Teva : EPAR - Risk-management-plan summary

Reference Number: EMA/639304/2014

English (EN) (411.39 KB - PDF)

**First published:** 04/12/2014

**Last updated:** 31/01/2017

[View](/en/documents/rmp-summary/budesonideformoterol-teva-epar-risk-management-plan-summary_en.pdf)

## Product information

Budesonide/Formoterol Teva : EPAR - Product Information

English (EN) (826.65 KB - PDF)

**First published:** 04/12/2014

**Last updated:** 31/01/2017

[View](/en/documents/product-information/budesonideformoterol-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-766)

български (BG) (1.57 MB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/bg/documents/product-information/budesonideformoterol-teva-epar-product-information_bg.pdf)

español (ES) (868.13 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/es/documents/product-information/budesonideformoterol-teva-epar-product-information_es.pdf)

čeština (CS) (1.17 MB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/cs/documents/product-information/budesonideformoterol-teva-epar-product-information_cs.pdf)

dansk (DA) (800.12 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/da/documents/product-information/budesonideformoterol-teva-epar-product-information_da.pdf)

Deutsch (DE) (872.95 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/de/documents/product-information/budesonideformoterol-teva-epar-product-information_de.pdf)

eesti keel (ET) (787.63 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/et/documents/product-information/budesonideformoterol-teva-epar-product-information_et.pdf)

ελληνικά (EL) (1.63 MB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/el/documents/product-information/budesonideformoterol-teva-epar-product-information_el.pdf)

français (FR) (901.88 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/fr/documents/product-information/budesonideformoterol-teva-epar-product-information_fr.pdf)

hrvatski (HR) (873.05 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/hr/documents/product-information/budesonideformoterol-teva-epar-product-information_hr.pdf)

íslenska (IS) (824.4 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/is/documents/product-information/budesonideformoterol-teva-epar-product-information_is.pdf)

italiano (IT) (785.48 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/it/documents/product-information/budesonideformoterol-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (1.17 MB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/lv/documents/product-information/budesonideformoterol-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (842.71 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/lt/documents/product-information/budesonideformoterol-teva-epar-product-information_lt.pdf)

magyar (HU) (1.19 MB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/hu/documents/product-information/budesonideformoterol-teva-epar-product-information_hu.pdf)

Malti (MT) (1.18 MB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/mt/documents/product-information/budesonideformoterol-teva-epar-product-information_mt.pdf)

Nederlands (NL) (838.23 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/nl/documents/product-information/budesonideformoterol-teva-epar-product-information_nl.pdf)

norsk (NO) (829.08 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/no/documents/product-information/budesonideformoterol-teva-epar-product-information_no.pdf)

polski (PL) (1.22 MB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/pl/documents/product-information/budesonideformoterol-teva-epar-product-information_pl.pdf)

português (PT) (852.55 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/pt/documents/product-information/budesonideformoterol-teva-epar-product-information_pt.pdf)

română (RO) (857.73 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/ro/documents/product-information/budesonideformoterol-teva-epar-product-information_ro.pdf)

slovenčina (SK) (1.16 MB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/sk/documents/product-information/budesonideformoterol-teva-epar-product-information_sk.pdf)

slovenščina (SL) (1.15 MB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/sl/documents/product-information/budesonideformoterol-teva-epar-product-information_sl.pdf)

Suomi (FI) (817.15 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/fi/documents/product-information/budesonideformoterol-teva-epar-product-information_fi.pdf)

svenska (SV) (818.27 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/sv/documents/product-information/budesonideformoterol-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** A31/0002 16/12/2016

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Budesonide/Formoterol Teva : EPAR - All Authorised presentations

English (EN) (148.9 KB - PDF)

**First published:** 04/12/2014

**Last updated:** 31/01/2017

[View](/en/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-385)

български (BG) (177.38 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/bg/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (154.67 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/es/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (167.8 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/cs/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (148.6 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/da/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (150.75 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/de/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (148.63 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/et/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (178.23 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/el/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (149.01 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/fr/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (156.27 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/hr/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (149.36 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/is/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (149.61 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/it/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (176.69 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/lv/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (163.9 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/lt/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (158.21 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/hu/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (171.76 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/mt/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (148.84 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/nl/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (146.07 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/no/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (162.91 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/pl/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (147.19 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/pt/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (164.81 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/ro/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (169.72 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/sk/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (160.28 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/sl/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (149.3 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/fi/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (151.69 KB - PDF)

**First published:**

04/12/2014

**Last updated:**

31/01/2017

[View](/sv/documents/all-authorised-presentations/budesonideformoterol-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Budesonide/Formoterol Teva Active substance

- Budesonide
- formoterol fumarate dihydrate

International non-proprietary name (INN) or common name

- budesonide
- formoterol

Therapeutic area (MeSH)

- Pulmonary Disease, Chronic Obstructive
- Asthma

Anatomical therapeutic chemical (ATC) code R03AK07

### Pharmacotherapeutic group

Drugs for obstructive airway diseases

### Therapeutic indication

Budesonide/Formoterol Teva is indicated in adults 18 years of age and older only.

**Asthma**

- in patients not adequately controlled with inhaled corticosteroids and \"as needed\" inhaled short-acting ?2 adrenoceptor agonists. or
- in patients already adequately controlled on both inhaled corticosteroids and long-acting ?2 adrenoceptor agonists.

**COPD** Symptomatic treatment of patients with severe COPD (FEV1 &lt; 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

## Authorisation details

EMA product number EMEA/H/C/003951 Marketing authorisation holder

Teva Pharma B.V.

Computerweg 10 3542 DR Utrecht The Netherlands

Marketing authorisation issued 19/11/2014 Withdrawal of marketing authorisation 16/12/2016 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Budesonide/Formoterol Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (222.74 KB - PDF)

**First published:** 09/10/2015

**Last updated:** 31/01/2017

[View](/en/documents/procedural-steps-after/budesonideformoterol-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Budesonide/Formoterol Teva : EPAR - Scientific Conclusion

English (EN) (184.47 KB - PDF)

**First published:** 15/07/2016

**Last updated:** 31/01/2017

[View](/en/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_en.pdf)

[Other languages (22)](#file-language-dropdown-830)

български (BG) (258.44 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/bg/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_bg.pdf)

español (ES) (185.55 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/es/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_es.pdf)

čeština (CS) (240.13 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/cs/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_cs.pdf)

dansk (DA) (183.32 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/da/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_da.pdf)

Deutsch (DE) (188.6 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/de/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_de.pdf)

eesti keel (ET) (190.99 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/et/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_et.pdf)

ελληνικά (EL) (267.25 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/el/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_el.pdf)

français (FR) (185.95 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/fr/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_fr.pdf)

hrvatski (HR) (215.19 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/hr/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_hr.pdf)

italiano (IT) (182.71 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/it/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_it.pdf)

latviešu valoda (LV) (239.48 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/lv/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_lv.pdf)

lietuvių kalba (LT) (217.79 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/lt/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_lt.pdf)

magyar (HU) (227.4 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/hu/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_hu.pdf)

Malti (MT) (244.94 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/mt/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_mt.pdf)

Nederlands (NL) (184.25 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/nl/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_nl.pdf)

polski (PL) (221.03 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/pl/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_pl.pdf)

português (PT) (184.53 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/pt/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_pt.pdf)

română (RO) (218.31 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/ro/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_ro.pdf)

slovenčina (SK) (239.17 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/sk/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_sk.pdf)

slovenščina (SL) (233.71 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/sl/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_sl.pdf)

Suomi (FI) (182.58 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/fi/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_fi.pdf)

svenska (SV) (184.6 KB - PDF)

**First published:**

15/07/2016

**Last updated:**

31/01/2017

[View](/sv/documents/scientific-conclusion/budesonideformoterol-teva-epar-scientific-conclusion_sv.pdf)

Budesonide/Formoterol Teva-H-C-3951-A31-14165: EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/330021/2016

English (EN) (228.27 KB - PDF)

**First published:** 15/07/2016

**Last updated:** 15/07/2016

[View](/en/documents/variation-report/budesonideformoterol-teva-h-c-3951-a31-14165-epar-assessment-report-article-31_en.pdf)

## Initial marketing authorisation documents

Budesonide/Formoterol Teva : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/707207/2014

English (EN) (1.92 MB - PDF)

**First published:** 04/12/2014

**Last updated:** 31/01/2017

[View](/en/documents/assessment-report/budesonideformoterol-teva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Budesonide / Formoterol Teva

Adopted

Reference Number: EMA/CHMP/436479/2014

English (EN) (215.7 KB - PDF)

**First published:** 26/09/2014

**Last updated:** 31/01/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-budesonide-formoterol-teva_en.pdf)

#### News on Budesonide/Formoterol Teva

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 May 2015](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-4-7-may-2015) 08/05/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 September 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-september-2014) 26/09/2014

**This page was last updated on** 31/01/2017

## Share this page

[Back to top](#main-content)